Esperion Announces FDA Confirmation of Regulatory Pathway to Approval for the Combination of Bempedoic Acid and Ezetimibe
June 26, 2017 16:05 ET
|
Esperion Therapeutics, Inc.
– Complementary, Non-statin, Oral Bempedoic Acid / Ezetimibe Combination Therapy Demonstrates 48% Lowering of LDL-C and Significant hsCRP Reduction with Potential for Lower Occurrence of...
Esperion to Present at the JMP Securities 2017 Life Sciences Conference
June 14, 2017 16:30 ET
|
Esperion Therapeutics, Inc.
Presentation and Webcast on Wednesday, June 21, 2017 at 10:00 a.m. Eastern Time ANN ARBOR, Mich., June 14, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management...
Esperion to Present at the Jefferies 2017 Global Healthcare Conference
May 31, 2017 16:30 ET
|
Esperion Therapeutics, Inc.
Presentation on Wednesday, June 7, 2017 at 10:30 a.m. Eastern Time ANN ARBOR, Mich., May 31, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused...
Esperion Provides Update on Common Stock Trading Activity
May 22, 2017 08:05 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., May 22, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary,...
Esperion to Participate in Fireside Chat at the UBS Global Healthcare Conference
May 19, 2017 16:30 ET
|
Esperion Therapeutics, Inc.
Fireside Chat Webcast on Tuesday, May 23, 2017 at 9:00 a.m. Eastern Time ANN ARBOR, Mich., May 19, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid...
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 18, 2017 16:30 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., May 18, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary,...
Esperion to Participate in Fireside Chat at the Bank of America Merrill Lynch 2017 Healthcare Conference
May 12, 2017 16:30 ET
|
Esperion Therapeutics, Inc.
Fireside Chat on Wednesday, May 17, 2017 at 3:40 p.m. Pacific Time/6:40 p.m. Eastern Time ANN ARBOR, Mich., May 12, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid...
Esperion to Participate in Fireside Chat at the 16th Annual Needham Healthcare Conference
March 28, 2017 16:30 ET
|
Esperion Therapeutics, Inc.
Fireside Chat on Tuesday, April 4, 2017 at 1:40 p.m. Eastern Time ANN ARBOR, Mich., March 28, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the lipid management company...
Esperion Announces FDA Confirmation Regarding Regulatory Pathway to Approval for an LDL-C Lowering Indication for Bempedoic Acid
March 20, 2017 07:30 ET
|
Esperion Therapeutics, Inc.
- Global Pivotal Phase 3 Program Design Can Support Approval for an LDL-C Lowering Indication - - Proposed LDL-C Lowering Indication Will Include Patients with High CVD Risk, Specifically Those...
Esperion Announces Initiation of Phase 2 Triplet Oral Therapy Study of Bempedoic Acid/Ezetimibe/Atorvastatin
March 07, 2017 08:30 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., March 07, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the lipid management company focused on developing and commercializing convenient, complementary,...